Cargando…
Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual Acuity
We investigated the long-term visual and anatomical outcomes of aflibercept monotherapy for exudative age-related macular degeneration (AMD) with good baseline best-corrected visual acuity (BCVA). A medical chart review was performed for 40 consecutive patients with baseline decimal BCVA ≥ 0.6 secon...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961756/ https://www.ncbi.nlm.nih.gov/pubmed/33807964 http://dx.doi.org/10.3390/jcm10051098 |
_version_ | 1783665330854297600 |
---|---|
author | Kikushima, Wataru Sakurada, Yoichi Sugiyama, Atsushi Yoneyama, Seigo Matsubara, Mio Fukuda, Yoshiko Kashiwagi, Kenji |
author_facet | Kikushima, Wataru Sakurada, Yoichi Sugiyama, Atsushi Yoneyama, Seigo Matsubara, Mio Fukuda, Yoshiko Kashiwagi, Kenji |
author_sort | Kikushima, Wataru |
collection | PubMed |
description | We investigated the long-term visual and anatomical outcomes of aflibercept monotherapy for exudative age-related macular degeneration (AMD) with good baseline best-corrected visual acuity (BCVA). A medical chart review was performed for 40 consecutive patients with baseline decimal BCVA ≥ 0.6 secondary to exudative AMD. Three monthly injections were administrated, and thereafter additional injection was performed if needed over 5 years. In total, 13 eyes with neovascular AMD (nAMD) and 27 eyes with polypoidal choroidal vasculopathy (PCV) were enrolled. In both groups, the mean BCVA significantly improved at the 12-month visit (p < 0.05). However, the significant improvement in BCVA disappeared at the 24-month visit, and the final mean BCVA was equivalent to that at baseline (p = 0.17 in the nAMD group and p = 0.15 in the PCV group). The median number of injections required after the loading dose was 15.0 during the 5-year follow-up (nAMD:15.0 vs. PCV:15). During the study period, 37 (92.5%) eyes required retreatment(s). Cox regression analysis demonstrated that the protective allele of ARMS2 A69S was associated with a retreatment-free period from the initial injection (p = 0.041, repeated forward selection method). As-needed aflibercept monotherapy is a preferable treatment option for exudative AMD with good initial visual acuity regardless of nAMD or PCV during the 5-year study period. |
format | Online Article Text |
id | pubmed-7961756 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79617562021-03-17 Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual Acuity Kikushima, Wataru Sakurada, Yoichi Sugiyama, Atsushi Yoneyama, Seigo Matsubara, Mio Fukuda, Yoshiko Kashiwagi, Kenji J Clin Med Article We investigated the long-term visual and anatomical outcomes of aflibercept monotherapy for exudative age-related macular degeneration (AMD) with good baseline best-corrected visual acuity (BCVA). A medical chart review was performed for 40 consecutive patients with baseline decimal BCVA ≥ 0.6 secondary to exudative AMD. Three monthly injections were administrated, and thereafter additional injection was performed if needed over 5 years. In total, 13 eyes with neovascular AMD (nAMD) and 27 eyes with polypoidal choroidal vasculopathy (PCV) were enrolled. In both groups, the mean BCVA significantly improved at the 12-month visit (p < 0.05). However, the significant improvement in BCVA disappeared at the 24-month visit, and the final mean BCVA was equivalent to that at baseline (p = 0.17 in the nAMD group and p = 0.15 in the PCV group). The median number of injections required after the loading dose was 15.0 during the 5-year follow-up (nAMD:15.0 vs. PCV:15). During the study period, 37 (92.5%) eyes required retreatment(s). Cox regression analysis demonstrated that the protective allele of ARMS2 A69S was associated with a retreatment-free period from the initial injection (p = 0.041, repeated forward selection method). As-needed aflibercept monotherapy is a preferable treatment option for exudative AMD with good initial visual acuity regardless of nAMD or PCV during the 5-year study period. MDPI 2021-03-05 /pmc/articles/PMC7961756/ /pubmed/33807964 http://dx.doi.org/10.3390/jcm10051098 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kikushima, Wataru Sakurada, Yoichi Sugiyama, Atsushi Yoneyama, Seigo Matsubara, Mio Fukuda, Yoshiko Kashiwagi, Kenji Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual Acuity |
title | Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual Acuity |
title_full | Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual Acuity |
title_fullStr | Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual Acuity |
title_full_unstemmed | Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual Acuity |
title_short | Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual Acuity |
title_sort | five-year outcome of aflibercept monotherapy for exudative age-related macular degeneration with good baseline visual acuity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961756/ https://www.ncbi.nlm.nih.gov/pubmed/33807964 http://dx.doi.org/10.3390/jcm10051098 |
work_keys_str_mv | AT kikushimawataru fiveyearoutcomeofafliberceptmonotherapyforexudativeagerelatedmaculardegenerationwithgoodbaselinevisualacuity AT sakuradayoichi fiveyearoutcomeofafliberceptmonotherapyforexudativeagerelatedmaculardegenerationwithgoodbaselinevisualacuity AT sugiyamaatsushi fiveyearoutcomeofafliberceptmonotherapyforexudativeagerelatedmaculardegenerationwithgoodbaselinevisualacuity AT yoneyamaseigo fiveyearoutcomeofafliberceptmonotherapyforexudativeagerelatedmaculardegenerationwithgoodbaselinevisualacuity AT matsubaramio fiveyearoutcomeofafliberceptmonotherapyforexudativeagerelatedmaculardegenerationwithgoodbaselinevisualacuity AT fukudayoshiko fiveyearoutcomeofafliberceptmonotherapyforexudativeagerelatedmaculardegenerationwithgoodbaselinevisualacuity AT kashiwagikenji fiveyearoutcomeofafliberceptmonotherapyforexudativeagerelatedmaculardegenerationwithgoodbaselinevisualacuity |